Cabral, a director at Doximity, Inc. (NYSE:DOCS), sold 7,500 shares of Class A Common Stock on August 7, according to an SEC Form 4 filing. Transaction value based on SEC Form 4 weighted average sale price ($39.11); post-transaction value based on the August 7 market close ($27.40). What governed the timing of this transaction?The sale was executed automatically under a Rule 10b5-1 trading plan adopted on February 19, which established pre-determined parameters for equity liquidation to minimize the potential for non-public information influence.
How does this affect the insider's total equity position?While the sale reduced direct common stock holdings to 3,221 shares, Cabral continues to hold 326,000 direct derivative securities, maintaining a significant long-term interest in the firm. Note that these figures refer to direct ownership only. What is the current performance context for the security?As of the August 7 transaction date, the stock had delivered a one-year return of -50%.
Shares were priced at $25.63 as of the August 10 market close. Share Price (as of market close 2026-08-10) Doximity operates a cloud-based digital platform that provides healthcare practitioners with specialized tools for peer networking, patient care management, remote consultations, access to medical research, and professional development. The company generates revenue through a subscription-based model serving pharmaceutical companies and healthcare organizations that utilize the platform's engagement and communication capabilities.
The primary customer base consists of pharmaceutical companies seeking practitioner engagement and healthcare organizations requiring digital health infrastructure solutions. Doximity is a leading digital health platform serving the U.S. healthcare practitioner market with a market capitalization of $4.8 billion and TTM revenue of $655.6 million. The company maintains strong profitability with TTM net income of $167.0 million.
As a specialized healthcare information services provider, Doximity leverages its established network of healthcare professionals to build a defensible platform that generates recurring revenue from enterprise customers. These shares went out the door the day after earnings, when the stock popped a pretty staggering 33%, but the plan behind the trade dates to February, so nobody timed anything here. It's worth noting, anyway, that this leaves Cabral with 3,221 shares of common stock, which is close to nothing, but a director's real exposure usually sits in options rather than shares, and those options certainly exist here.The quarter he sold into was positive, but with interesting underlying dynamics.
Revenue rose 7% to $156.6 million, but free cash flow fell 34% to $39.6 million, with accounts receivable climbing more than $33 million over three months. Management chalked it up to collection timing and expects it to even out beginning this quarter.Meanwhile, the revenue base is narrower than the platform framing suggests. 127 pharma and hospital customers spending north of $500,000 each produced 83% of total revenue last quarter, with overall net revenue retention at 107%. Perry Gold, the senior VP of investor relations, told analysts there's "the velocity of the business that we haven't felt in a few quarters." Long-term investors should stay focused on how that ultimately pans out.
Extract — continue reading at the source.
